Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.45    0.00 (0.00%)
Bid:
8.30
Ask:
8.60
Spread: 0.30 (3.614%)
Market Cap: £18.43m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Re Agreement

26 Jun 2007 07:02

Phytopharm PLC26 June 2007 Company Contact: U.K. Investor Relations Contact:Phytopharm plc FDDr Daryl Rees CEO David YatesMr Piers Morgan CFO Ben Atwell+44 1480 437 697 +44 207 831 3113www.phytopharm.com Collaboration and Licence Agreement with The Beijing Institute for novel memoryand concentration product GODMANCHESTER, Cambridgeshire, U.K. (26 June 2007) - Phytopharm plc (LSE: PYM)("Phytopharm" or the "Company") announces today a Collaboration and LicenceAgreement with The Beijing Institute, Academy of Military Medical Sciences ("TheBeijing Institute") for the development of novel functional foods andpharmaceuticals, including a product for memory and concentration. Under the terms of the Collaboration and Licence Agreement, Phytopharm and TheBeijing Institute will collaborate to progress The Beijing Institute's leadproduct for memory and concentration selected from its library of patentedcompounds derived from Traditional Chinese Medicine. The Collaboration andLicence Agreement also extends to certain other patented compounds that may haveutility in other disease areas including vascular disorders and stroke.Phytopharm has been granted an exclusive licence from The Beijing Institute todevelop and commercialize these products globally in return for royalty andmilestone payments to The Beijing Institute upon the achievement of certainpre-defined goals. Financial terms of the agreement are not disclosed. Traditional Chinese Medicines have been used for thousands of years and overthat time a wealth of knowledge and expertise in the medicinal use of plants hasbuilt up. The Beijing Institute scientists have extensive knowledge ofTraditional Chinese Medicines and their research over the last 10 years has ledto the identification of a lead product that has the potential to improve memoryand concentration. Phytopharm will develop this lead product through furtherpre-clinical testing and progress into clinical trials. Commenting on today's announcement, Dr Xiaoming Yang, Head of The BeijingInstitute, said: "We are delighted to be working with Phytopharm and proud thatThe Beijing Institute's extensive expertise and experience in TraditionalChinese Medicine has been recognized by Phytopharm and we look forward to a longand fruitful collaboration." Commenting on today's announcement, Dr Daryl Rees, Chief Executive Officer ofPhytopharm, said: "We are excited about the Collaboration and Licence Agreementwith The Beijing Institute as it fulfils one of our strategic objectives ofexpanding our product portfolio with a novel functional food candidate formemory and concentration, an area in which we have established expertise. TheBeijing Institute's scientists bring significant knowledge on TraditionalChinese Medicine and we look forward to working with them to advance the leadproduct through clinical development." -Ends- Notes to Editors Phytopharm plc Phytopharm is a pharmaceutical development and functional food company whoseproduct leads are generated from medicinal plants. The Company's strategy is todevelop these products through 'proof of principle' clinical testing, and thensecure partners for late stage development, sales and marketing. Laboratory,manufacturing and clinical work is outsourced to selected specialists, operatingunder expert in-house management. This operational structure allows access tothe best external research facilities whilst maintaining low fixed overheads anda lower development cost structure. Beijing Institute The Beijing Institute (Institute of Radiation Medicine, the Academy of MilitaryMedical Sciences, Beijing) has over the past 50 years developed its researchstrengths from radiobiology into a wide range of scientific fields, includingbiotechnology, biochemistry, molecular biology, pharmaceutical chemistry,pharmacology, toxicology, experimental pathology, experimental haematology,genomics and proteomics. These groups were set up to provide the qualitycontrol for Traditional Chinese Medicine products and the identification anddevelopment of extracted active compounds. The Institutes considerableexpertise and experience in the extraction of active compounds from TraditionalChinese Medicine has resulted in several pharmaceutical products beingsuccessfully developed for the Chinese market. Functional Foods Functional foods are foodstuffs that provide health or physiological benefitsabove their nutritional value and have a health claim on the packaging.Currently gut and heart health products dominate with new interest in areas ofweight control, memory and concentration, immune system function and skinhealth. The global value of functional foods is estimated to be up to $65bn.The growth potential is predicted to be 50% from 2005-2010 with an acceleratingtrend for new products. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
19th Jan 20112:14 pmRNSDirector/PDMR Shareholding
19th Jan 20112:14 pmRNSDirector/PDMR Shareholding
14th Jan 201110:18 amRNSHolding(s) in Company
10th Jan 201111:45 amRNSHolding(s) in Company
7th Jan 20111:50 pmRNSBlock Listing Application
7th Jan 201110:59 amRNSBlocklisting Application
4th Jan 20112:01 pmRNSTotal Voting Rights
21st Dec 201012:19 pmRNSDirector/PDMR Shareholding
21st Dec 201012:18 pmRNSDirector/PDMR Shareholding
14th Dec 20101:15 pmRNSBlock Listing Application
30th Nov 20107:00 amRNSFinal Results
17th Nov 201011:44 amRNSResearch Update
3rd Nov 20109:29 amRNSBlocklisting Interim Review
1st Nov 20104:31 pmRNSPreliminary Results - Change of Date
1st Nov 201010:41 amRNSNotice of Results
29th Sep 20102:00 pmRNSPresents Cogane data at scientific conferences
18th Aug 20107:00 amRNSInterim Management Statement
22nd Jul 20101:49 pmRNSDirector/PDMR Shareholding
22nd Jul 20101:49 pmRNSDirector/PDMR Shareholding
5th Jul 201010:59 amRNSChange of Registered Office
21st Jun 20107:00 amRNSAppointment of Chief Executive Officer
14th Jun 20107:00 amRNSRegulatory Approval to Begin Cogane PII Trial
24th May 20107:00 amRNSHalf Yearly Report
19th May 20104:25 pmRNSNotice of Results
4th May 20102:13 pmRNSBlocklisting Interim Review
1st Apr 201012:36 pmRNSDirector/PDMR Shareholding
1st Apr 201012:35 pmRNSDirector/PDMR Shareholding
1st Apr 201012:34 pmRNSDirector/PDMR Shareholding
31st Mar 201012:19 pmRNSResult of AGM
2nd Mar 20108:25 amRNSNotice of AGM
11th Feb 20107:00 amRNSInterim Management Statement
15th Jan 20107:00 amRNSDirectorate Change
5th Jan 20109:10 amRNSHolding(s) in Company
4th Jan 201010:29 amRNSTotal Voting Rights
31st Dec 20099:26 amRNSDirector/PDMR Shareholding
31st Dec 20099:25 amRNSDirector/PDMR Shareholding
31st Dec 20099:25 amRNSDirector/PDMR Shareholding
31st Dec 20099:25 amRNSDirector/PDMR Shareholding
29th Dec 20093:27 pmRNSResult of EGM
22nd Dec 20097:00 amRNSResult of Open Offer
15th Dec 20093:12 pmRNSCorrection to the Form of Proxy
15th Dec 20099:00 amRNSAnnual Information Update
14th Dec 20097:00 amRNSPresents data at XVIII WFN World Congress
3rd Dec 20095:18 pmRNSPublication of Prospectus
3rd Dec 20097:05 amRNSPlacing and Open Offer to Raise ?25.2 million
3rd Dec 20097:00 amRNSReport and Accounts 2009 - Part 3
3rd Dec 20097:00 amRNSReport and Accounts 2009 - Part 2
3rd Dec 20097:00 amRNSReport and Accounts 2009 - Part 1
12th Nov 20093:59 pmRNSBlocklisting Interim Review
4th Nov 20091:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.